Drug Profile
Research programme: orphan nuclear receptor antagonists - Orphagen Pharmaceuticals
Latest Information Update: 07 Jul 2020
Price :
$50
*
At a glance
- Originator Orphagen Pharmaceuticals
- Class Antianaemics; Antidepressants; Antineoplastics; Antisecretories; Anxiolytics; Eye disorder therapies; Sleep disorder therapies; Small molecules
- Mechanism of Action Orphan nuclear receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Adrenocortical carcinoma; Cushing syndrome
- No development reported Anxiety disorders; Cancer; Depressive disorders; Dry age-related macular degeneration; Endometriosis; Retinitis pigmentosa; Sickle cell anaemia; Sleep disorders
Most Recent Events
- 07 Jul 2020 Preclinical trials in Adrenocortical carcinoma in USA (PO) before July 2020 (Orphagen Pharmaceuticals pipeline, July 2020)
- 07 Jul 2020 Preclinical trials in Cushing syndrome in USA (unspecified route) before July 2020 (Orphagen Pharmaceuticals pipeline, July 2020)
- 28 Nov 2019 No recent reports of development identified for research development in Sickle-cell-anaemia in USA